Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05050942 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET

Study acronym: SORENTO
StatusActive, Not Recruiting
PhasePhase 3
SponsorCamurus AB
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 3 months later Jul 2026 → Nov 2026
See other at-risk trials from Camurus AB

Record History

  1. Primary completion pushed from Jul 2026 to Nov 2026
    • Study completion pushed from Jul 2028 to Nov 2028
    v20
  2. Study sites: 98 to 86v19
  3. Primary completion date: Dec 2025 to Jul 2026
    • Study completion date: Dec 2027 to Jul 2028
    v18
  4. Primary completion date: Dec 2024 to Dec 2025
    • Study completion date: Dec 2026 to Dec 2027
    v17
  5. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 300 to confirmed 332
    • Study sites: 103 to 98
    v16
Show 14 earlier versionsHide 14 earlier versions
  1. Study sites: 101 to 103v15
  2. Study sites: 99 to 101v14
  3. Study sites: 95 to 99v13
  4. Study sites: 89 to 95v12
  5. Study sites: 83 to 89v11
  6. Study sites: 73 to 83v10
  7. Study sites: 56 to 73v9
  8. Study sites: 42 to 56v8
  9. Study sites: 33 to 42v7
  10. Study sites: 14 to 33v6
  11. Study sites: 9 to 14v5
  12. Study sites: 8 to 9v4
  13. Study sites: 6 to 8v3
  14. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 6
    • Start date changed from estimate of Sep 2021 to Oct 22, 2021
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Camurus AB
4 trials monitored
See 1 trial at risk
The purpose of this study is to compare the effectiveness and safety of CAM2029 to octreotide LAR or lanreotide ATG in patients with advanced, well-differentiated GEP-NET. Patients who experience progressive disease in the randomized part of the study may proceed to an open-label extension part with intensified treatment with CAM2029.
Trial Details
NCT Number NCT05050942
Lead Sponsor Camurus AB
Conditions
(from sponsor)		 Gastro-enteropancreatic Neuroendocrine Tumor
Related terms Gastro-enteropancreatic neuroendocrine tumor
Enrollment 332 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov